Pluri Inc
Company Profile
Business description
Pluri Inc is a biotechnology company engaged in the research, development, and manufacturing of cell-based products, as well as the commercialization of cell therapeutics and related technologies aimed at delivering solutions across a range of industries, including regenerative medicine, immunotherapy, food tech, CDMO, and AgTech. The company uses its 3D cell expansion technology platform to develop placenta-based cell therapy product candidates (PLX-PAD and PLX-R18) for the treatment of inflammatory, muscle injuries, and hematologic conditions. In addition, it offers CDMO services through PluriCDMO, has launched a novel immunotherapy platform, and is engaged in developing cultivated, cell-cultured coffee and meat.
Contact
MATAM Advanced Technology Park
Building No. 5
Haifa3508409
ISRT: +972 747108600
Sector
Healthcare
Stock type
Defensive
Industry
Biotechnology
Fiscal Year End
30 June 2027
Employees
113
Stocks News & Analysis
stocks
Samsung and SK Hynix lead chip selloff as China competition fears grow
stocks
Updating our assumed commodity prices and fair values of the two largest Aussie miners
Morningstar Investment Ideas
Markets
Index | Last price | Change | % Change |
|---|---|---|---|
| All Ordinaries | 8,869.00 | 52.50 | -0.59% |
| CAC 40 | 7,873.11 | 45.48 | 0.58% |
| DAX 40 | 25,322.48 | 62.58 | 0.25% |
| Dow JONES (US) | 51,599.19 | 70.91 | -0.14% |
| FTSE 100 | 10,724.86 | 74.53 | 0.70% |
| HKSE | 24,314.17 | 31.05 | -0.13% |
| NASDAQ | 26,839.63 | 364.75 | -1.34% |
| Nikkei 225 | 67,744.29 | 33.23 | -0.05% |
| NZX 50 Index | 13,760.39 | 10.79 | 0.08% |
| S&P 500 | 7,733.21 | 72.24 | -0.93% |
| S&P/ASX 200 | 8,727.90 | 56.00 | -0.64% |
| SSE Composite Index | 3,767.23 | 33.64 | -0.88% |